Treatment with other PI3K inhibitors (BYL719 and TGX221) could also mimic the sensitization mediated by ZSTK474, suggesting that blockade of the PI3K pathway is effective in sensitizing tumor cells to TMZ. The gene discussed is PIK3CA; the disease is neoplasm.